We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Bracco Diagnostics Acquires E-Z-EM

By HospiMedica staff writers
Posted on 31 Oct 2007
Bracco Diagnostics, a US based subsidiary of Bracco Imaging, S.p.A and part of the Bracco group, announced the acquisition of E-Z-EM, a recognized contrast agent manufacturer for diagnostic imaging of the GI tract.

E-Z-EM and Bracco Diagnostics have a longstanding association: E-Z-EM manufactures an oral imaging product for Bracco, and Bracco, as distributors, represents E-Z-EM in Italy. Bracco Diagnostics is one of the world's leading companies in the imaging agent business, while E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. In addition, it is worth noting that E-Z-EM was named among the Best Small Companies in America in 2007 by Forbes magazine.

Both companies are well positioned with respected brands in the marketplace and the expected synergies from the merger will certainly enhance their standing. Bracco believes in the strong strategic fit of E-Z-EM to strengthen its core business and to consolidate its presence in the sector. In fact, the merger represent an initiative pursued by the E-Z-EM board of directors as the best alternative to increase shareholder value.

Under the terms of the agreement, Bracco will acquire all outstanding shares of E-Z-EM for US$21 per share for a total consideration of nearly $241 million. Subject to a majority vote by E-Z-EM shareholders and U.S. regulatory approval, the transaction will close sometime early in 2008, with a merger by incorporation of E-Z-EM into Bracco Diagnostics.

E-Z-EM (Lake Success, NY, USA) is a leading manufacturer of contrast agents for radiology and the developer of VoLumen, a next generation low-density barium sulfate suspension for use as an oral contrast in Multidetector CT (MDCT) and Positron Emission Tomography (PET/CT) studies. E-Z-EM is also the worldwide manufacturer and marketer of Reactive Skin Decontamination Lotion (RSDL), a broad-spectrum liquid chemical warfare agent decontaminant.

Bracco Diagnostics, Inc., (Princeton, NJ, USA) one of the world's leading companies in the imaging agent business, is a US subsidiary of Bracco Imaging S.p.A of Milan, Italy, which also markets ethical, and OTC pharmaceutical products and healthcare services in Italy, as well as advanced medical technology systems on a worldwide basis.


Related Links:
E-Z-EM
Bracco Diagnostics

New
Gold Member
X-Ray QA Meter
T3 AD Pro
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Digital Radiographic System
OMNERA 300M
New
Transducer Covers
Surgi Intraoperative Covers

Latest Business News

Boston Scientific Acquires Medical Device Company Intera Oncology

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024